OSLM
Outcome Studies
in Laboratory Medicine
guest
👤
Learn more about this platform
c
Categories
p
Projects
Trial protocol
Highlighted
Study Design
RCT
Cluster RCT
Observational
Model
Meta-analysis
Review
Guideline
Outcomes
Change patient management
Clinical outcomes
Economics
Operational efficiencies
Patient-centeredness
Safety
Guide Policy Making
Other
Uncategorized
Antibiotic Guidance
ACT Guided Heparinization
Cancer
COVID-19
Cardiovascular Disease
Diabetes
HIV POCT
Inflammatory Bowel Disease
Liver Disease
Kidney Disease
Newborn Screening
MALDI-TOF MS For Microorganism Identification
Preeclampsia
Pharmacogenetic and Pharmacogenomics
Therapeutic drug monitoring
Viscoelastic Testing
Please contact us for any suggestions
Zhen Zhao
Smeralda Skenderaj
Search
Search
Project:
Cancer
Categories:
Economics
Model
20 Publications
found
Molecular-Guided Off-Label Targeted Therapy in a Large-Scale Precision Oncology Program.
b
JCO precision oncology
February 1, 2023
p
Cancer
c
Clinical outcomes
Economics
Highlighted
Model
Cost-Effectiveness and Budget Impact of Future Developments With Whole-Genome Sequencing for Patients With Lung Cancer.
b
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
January 1, 2023
p
Cancer
c
Economics
Model
A global analysis of the value of precision medicine in oncology – The case of non-small cell lung cancer.
b
Frontiers in medicine
January 1, 2023
p
Cancer
c
Economics
Highlighted
Model
Quantifying the Impact of Capacity Constraints in Economic Evaluations: An Application in Precision Medicine.
b
Medical decision making : an international journal of the Society for Medical Decision Making
May 1, 2022
p
Cancer
c
Economics
Model
Clinical and economic impact of ‘ROS1-testing’ strategy compared to a ‘no-ROS1-testing’ strategy in advanced NSCLC in Spain.
b
BMC cancer
March 19, 2022
p
Cancer
c
Economics
Model
Early Cost Effectiveness of Whole-Genome Sequencing as a Clinical Diagnostic Test for Patients with Inoperable Stage IIIB,C/IV Non-squamous Non-small-Cell Lung Cancer.
b
PharmacoEconomics
December 1, 2021
p
Cancer
c
Economics
Model
Clinical and economic impact of current ALK rearrangement testing in Spain compared with a hypothetical no-testing scenario.
b
BMC cancer
June 10, 2021
p
Cancer
c
Clinical outcomes
Economics
Model
EGFR mutation-guided use of afatinib, erlotinib and gefitinib for advanced non-small-cell lung cancer in Hong Kong – A cost-effectiveness analysis.
b
PloS one
January 1, 2021
p
Cancer
c
Economics
Model
Cost-effectiveness of ALK testing and first-line crizotinib therapy for non-small-cell lung cancer in China.
b
PloS one
January 1, 2018
p
Cancer
c
Economics
Model
The effect of PD-L1 testing on the cost-effectiveness and economic impact of immune checkpoint inhibitors for the second-line treatment of NSCLC.
b
Annals of oncology : official journal of the European Society for Medical Oncology
September 1, 2017
p
Cancer
c
Economics
Highlighted
Model
1
2
Next Page
